Ayu最新文献

{"title":"Azadirachta indica A. juss, Morinda citrifolia L. and Triphala as herbal endodontic irrigants: A scoping review","authors":"A. Agnihotri, S. Jhamb, Urvashi Shrama, Sumidha Rohtagi","doi":"10.4103/ayu.AYU_102_20","DOIUrl":"https://doi.org/10.4103/ayu.AYU_102_20","url":null,"abstract":"Background: The success of the root canal treatment depends on the complete elimination of the microflora, biofilms and smear layer from the pulp space. A wide variety of chemical endodontic irrigants are available to achieve disinfection and thorough debridement besides mechanical means. However, detrimental properties such as allergic potential, cytotoxicity, antimicrobial resistance and safety concerns have intrigued researchers over the years to look for safer options. Aim: The review is aimed at providing comprehensive information of the studies evaluating the efficacy of Azadirachta indica A. juss (A. indica), Morinda citrifolia L. (M. citrifolia) and Triphala (fruits of Emblica officinalis Gaertn., Terminalia chebula (Gaertn.) Roxb. and Terminalia belerica Retz.) as herbal endodontic irrigants. Materials and methods: The literature review was conducted using indexed databases (PubMed, Google Scholar, Cochrane) electronically for publications in peer-reviewed journals for relevant articles evaluating the efficacy of A. indica, Triphala, M. citrifolia as endodontic irrigant from the year 1985-March 2020. Results: A total of 58 studies were identified for full text reviewing after duplicate removal and screening title and abstracts. A total of 32 studies were included and processed for data extractions. Conclusion: Various in-vitro/in-vivo studies utilizing these herbal irrigants have documented promising results and hold the potential to replace chemical endodontic irrigants in routine practice but more preclinical and clinical trials are needed to substantiate these results before they can conclusively be recommended as intracanal irrigating solutions.","PeriodicalId":8720,"journal":{"name":"Ayu","volume":"75 1","pages":"148 - 158"},"PeriodicalIF":0.0,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80083420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Brimhana Nasya and Ashwagandha (Withania somnifera (L.) Dunal) root powder in primary insomnia in elderly male: A randomized open-label clinical study","authors":"Upadhyay Atul, Bansal Charu, S. Umesh","doi":"10.4103/ayu.AYU_177_19","DOIUrl":"https://doi.org/10.4103/ayu.AYU_177_19","url":null,"abstract":"Background: Decreased ability to fall asleep and/or stay asleep with daytime effects of sleep deprivation is identified as primary insomnia. Elderly due to the predominant Vata Dosha in the body are easily affected by this problem. Brimhana Nasya (nourishing nasal drop) with Ksheera Bala Taila and oral administration of Ashwagandha (Withania somnifera (L.) Dunal) root powder both are indicated in Ayurvedic classics for the management of insomnia. Aim: To determine the combined efficacy of oral administration of Ashwagandha root powder along with Brimhana Nasya with Ksheera Bala Taila in primary insomnia in geriatric. Materials and methods: This was randomized, open-label clinical study conducted at the hospital of Pt. Khushilal Sharma Government Ayurveda College and Institute Bhopal. Randomly selected 60 elderly patients with primary insomnia were randomly divided into two groups (30 in each group). Pittsburgh Sleep Quality Index was used to assess the symptoms of primary insomnia. Relief in the subjective symptoms was assessed in percentage. Then, the statistical significance of result within the group was assessed using Wilcoxon matched-pairs signed-ranks test and the comparative effect of therapy in both groups was assessed using Mann-Whitney test. Graph Pad InStat-3 software was used for statistical analysis. Results: On subjective sleep quality 86.66% relief with P < 0.0001, on sleep latency 60.02% improvement with P < 0.0001, improvement in sleep duration was reported in 89.15% of patients with P < 0.0001 and improvement in sleep efficiency was reported in 90.14% of patients with statistically extremely significant P < 0.0001 were observed in combined therapy group (Ksheera Bala Taila Brimhana Nasya along with oral administration of Ashwagandha root powder). While 38.66% improvement in sleep efficiency, 40.39% relief in sleep disturbances and 37.05% improvement on subjective sleep quality was reported in group B patients, i.e., Ashwagandha root powder group. Conclusion: In 30 days treatment combined therapy was found more effective in the management of primary insomnia in the elderly compared with Ashwagandha root powder alone.","PeriodicalId":8720,"journal":{"name":"Ayu","volume":"77 1","pages":"159 - 165"},"PeriodicalIF":0.0,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74666397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of Ayurveda trials registered with Clinical Trial Registry-India: Need for customized data set items","authors":"A. Juneja, T. Adhikari, M. V. Rao, Narayanam Srikanth, Saurabh Sharma, M. Maulik, Jyotsna Gupta, Yashmin Panchal, B. Rao, S. Khanduri, Rakesh Narayan, R. Bhardwaj, Prakriti Batra","doi":"10.4103/ayu.ayu_375_21","DOIUrl":"https://doi.org/10.4103/ayu.ayu_375_21","url":null,"abstract":"Background: Lack of research data is one of the major challenges identified in traditional medicine (TM). Further, there is an urgent need to strengthen and streamline clinical research processes as well as develop research databases in TM. The Clinical Trials Registry-India (CTRI), a free, online primary register of the WHO's International Clinical Trials Registry Platform, undertakes registration of all clinical trials being conducted in India, including TM trials. However, as the CTRI data set items are primarily designed to capture information of interventional trials of the conventional system of medicine, key fields relevant to the TM system are not adequately captured in the CTRI. Aims and Objectives: The current study was conceptualized with the objective to review the type and quality of trials registered in the CTRI as well as identify the specific data set items in CTRI which may be customized as per Ayurveda studies. Materials and methods: The trials registered from July 1, 2018, to March 31, 2020, were analyzed to decipher the kind of research being undertaken in the field of Ayurveda. These trials were manually reviewed independently by two Ayurveda reviewers to gain insights into the discrepancies. Along with these analysis, brainstorming sessions with Ayurveda experts were also held. Results: The fields which were identified and need tweaking and customization were the fields “health condition” and “intervention/comparator agent.” Conclusions: These modifications in the CTRI would enable the capture of more effective Ayurveda-specific information which would in turn help to standardize and streamline research practices as well as raise the standard of research.","PeriodicalId":8720,"journal":{"name":"Ayu","volume":"33 1","pages":"143 - 147"},"PeriodicalIF":0.0,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83172666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of <i>Opuntia elatior</i> Mill. (<i>Nagaphani</i>) in the management of <i>Pandu Roga</i> w. s. r to iron deficiency anemia; an open labeled randomized standard controlled clinical trial.","authors":"Shashikant M Prajapati,&nbsp;Sharada Anand,&nbsp;Rabinarayan Acharya,&nbsp;Mandip Goyal","doi":"10.4103/ayu.AYU_31_18","DOIUrl":"https://doi.org/10.4103/ayu.AYU_31_18","url":null,"abstract":"<p><strong>Background: </strong><i>Pandu Roga</i> described in <i>Ayurveda</i> bears resemblance to the clinical features of anemia. The fruits of <i>Nagaphani</i> (<i>Opuntia elatior</i> Mill.) of family <i>cactaceae</i>, are consumed by the inhabitants of Gujarat as a hematinic agent to treat general debility and anemia.</p><p><strong>Aim and objective: </strong>To evaluate the efficacy of the <i>O. elatior</i> fruit juice in <i>Pandu Roga</i> with special reference to iron deficiency anemia.</p><p><strong>Materials and method: </strong>Present clinical study was an open labeled, randomized trial, in which 105 patients of <i>Pandu Roga</i> (iron deficiency anemia), were divided into two groups using the coin method of randomization. Group A received <i>Opuntia elatior</i> fruit juice, 20 ml twice a day with lukewarm water before meal. Group B received <i>Punarnava Mandura</i> (standard control), well accepted after this a herbo-mineral fromulation, two tablets of 500 mg each, twice a day with <i>Takra</i> (butter milk) before meal. Duration of intervention was 2 months in both groups and a follow-up of 1 month. The assessment was done based on the clinical signs and symptoms and hematological parameters such as Hb% (hemoglobin %), total red blood cell (TRBC), serum iron, serum ferritin and total iron-binding capacity (TIBC), before and after completion of the treatment. The data were subjected to statistical tests (Wilcoxon signed-rank test and paired <i>t</i>-tests, co-efficient of variance (CV)), and analyzed.</p><p><strong>Results: </strong>Both trial drug and the standard drug produced a statistically significant increase in Hb%, TRBC and serum Iron. The standard drug provided statistically significant increase (<i>P</i> < 0.05) in TIBC, whereas a statistically insignificant (<i>P</i> > 0.05) effect was observed in the trial group. Both trial and standard drug provided statistically significant (<i>P</i> < 0.001) relief in <i>Panduta</i> (pallor), <i>Daurbalya</i> (general weakness), <i>Akshikutashotha</i> (periorbital edema) and <i>Pindikodveshthana</i> (calf muscle cramps). When compared between the groups, the standard drug was found to be more effective than the trial drug.</p><p><strong>Conclusion: </strong>Fruit juice of <i>Opuntia elatior</i> is effective in iron deficiency anemia as it increases the hemoglobin, TRBC levels in blood along with providing relief in <i>Panduta</i> (pallor), <i>Daurbalya</i> (general weakness) <i>Akshikutashotha</i> (periorbital edema).</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":"41 2","pages":"87-97"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/92/AYU-41-87.PMC8614203.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39839022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of concomitant use of <i>Ayurveda</i> and conventional anti-diabetic formulations - Experiences at a tertiary care <i>Ayurveda</i> hospital, India.","authors":"R Galib,&nbsp;Poonam Dang,&nbsp;Vijay Kumar,&nbsp;Rakesh Rana,&nbsp;Pramod Yadav,&nbsp;P K Prajapati","doi":"10.4103/ayu.AYU_81_20","DOIUrl":"https://doi.org/10.4103/ayu.AYU_81_20","url":null,"abstract":"<p><strong>Background: </strong>Majority of the population relies on traditional medicines for many of their health related problems. Particularly individuals with chronic illness like diabetes mellitus (DM) are more likely to simultaneously use herbal medicines. Many of such users believe that traditional medicines are natural and therefore safe, but this is a dangerous over simplification. Some herbal medicines may be associated with adverse effects, which include interactions with prescribed drugs. Information on such concomitant use of anti-diabetic drugs along with <i>Ayurveda</i> medicines is limited in Indian scenario.</p><p><strong>Aims and objectives: </strong>To survey the patterns of concomitant use of Ayurveda and conventional anti-diabetic drugs by diabetic patients attending an out-patient department of a tertiary care teaching hospital in New Delhi, India through a validated questionnaire.</p><p><strong>Materials and methods: </strong>This is a questionnaire-based survey, carried out after the approval of the Institutional Ethics Committee, subsequently registered at CTRI. A questionnaire to assess the pattern of concomitant use was developed; content was validated and pre-tested by a pilot study in 40 patients, further refined and used in the survey. The data was analyzed to evaluate the patterns of concomitant use of Ayurvedic and conventional anti-diabetic drugs.</p><p><strong>Results: </strong>About 95.9% of diabetic patients were taking herbo-mineral formulations concomitantly with conventional anti-diabetic drugs. Although 45.3% of diabetics were using Ayurveda interventions under the supervision of qualified AYUSH physicians, remaining involved in procuring the drugs over the counter (OTC) or from the local vendors. In majority of these instances, the use of <i>Ayurveda</i> formulations was not communicated with their physicians.</p><p><strong>Conclusion: </strong>The observations reveal that a majority of the diabetics (95.9%) were taking one or the other form of herbal preparations along with their conventional anti-diabetic drugs and about 44% among them were using these concomitantly. Thus, generating awareness on good practices of drug use seems to be essential.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":"41 2","pages":"72-78"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4a/bb/AYU-41-72.PMC8614209.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39838586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential of <i>Ayurveda</i> in the prevention and management of post-COVID complications.","authors":"Mandip Goyal","doi":"10.4103/ayu.ayu_284_21","DOIUrl":"https://doi.org/10.4103/ayu.ayu_284_21","url":null,"abstract":"COVID-19, a global pandemic has affected individuals to varying degrees, ranging from a few days of mild symptoms to respiratory distress requiring intensive care unit (ICU) treatment including ventilator support, and even death. Early in the pandemic, it was believed that COVID-19 was a short-term illness. In February 2020, the World Health Organization reported that from the onset to clinical recovery for mild cases the duration was approximately 2 weeks and that recovery took 3–6 weeks for patients with the severe or critical disease.[1] However, recently it has become clear that in some patients debilitating symptoms persist for weeks or even months. This means that a subset of people who have recovered from COVID-19 continue to experience symptoms that remain beyond testing negative for the virus. “Long-COVID” or “COVID long-haulers” or post-COVID Syndrome generally describes those persons with COVID-19 who experience symptoms for >28 days after diagnosis.[2] Though long‐term sequelae of COVID‐19 are unidentified, but evidence from previous outbreaks demonstrates that the most common conditions are impaired pulmonary and physical function, reduced quality of life and emotional distress, which indicates psychological, physical, and cognitive impairments and has huge downstream effects on a person’s quality of life-impacting family life and work productivity.","PeriodicalId":8720,"journal":{"name":"Ayu","volume":"41 2","pages":"69-71"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/f9/AYU-41-69.PMC8614207.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39838585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standard operating procedure of Purification of <i>Chitraka</i> (<i>Plumbago zeylanica</i> Linn.) along with pharmacognostical and analytical profiles of Plumbagin.","authors":"Sonam S Bhinde,&nbsp;Arun Kumar Ravi,&nbsp;Biswajyoti J Patgiri,&nbsp;C R Harisha,&nbsp;Vinay J Shukla","doi":"10.4103/ayu.AYU_299_20","DOIUrl":"https://doi.org/10.4103/ayu.AYU_299_20","url":null,"abstract":"<p><strong>Introduction: </strong><i>Shodhana</i> (purification) is the process by which one can remove the impurity or toxicity of the raw drug and make the drug suitable for therapeutic purpose. <i>Chitraka</i> (<i>Plumbago zeylanica</i> Linn.) is well known drug in Ayurveda and root of this plant is being used for therapeutic purpose and requires purification before used as a medicine.</p><p><strong>Aims and objective: </strong>There is no data available for pharmacognostical and analytical profile of processed <i>Chitraka</i>, hence it was planned to develop SOP of processed <i>Chitraka</i> for its identity, purity and strength through pharmacognostical and analytical profile.</p><p><strong>Materials and methods: </strong><i>Chitraka</i> roots were procured from Pharmacy, Gujarat Ayurved University, Jamnagar. Purification was done in five batches with Churnodaka (lime water). Organoleptic characters, microscopic features, pH, loss on drying, ash value, water soluble extracts, methanol soluble extracts and plumbagin quantification through high-performance thin layer chromatography (HPTLC) were carried out, before and after the purification.</p><p><strong>Results: </strong>Average 98.07% yield of <i>Chitraka</i> was obtained after purification. Differences were found in the processed samples of <i>Chitraka</i> in organoleptic features, pharmacognostical characters and physicochemical parameters, which show the impact of purification procedure on <i>Chitraka</i>. In HPTLC profile, plumbagin content was 0.29% in unpurified <i>Chitraka</i> powder, where in it was noted 0.98% after purification.</p><p><strong>Conclusion: </strong>Increase in plumbagin content through pharmaceutical process of <i>Chitraka</i> purification with lime water indicates that, this operating procedure is simple, convenient and can be considered as standard procedure. The organoleptic features, pharmacognostical characters, values of physicochemical parameters and quantity of plumbagin of purified <i>Chitraka</i> powder may be utilized for quality assurance in future studies.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":"41 2","pages":"117-122"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b1/46/AYU-41-117.PMC8614202.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39726022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AYUSH-64 as an add-on to standard care in asymptomatic and mild cases of COVID-19: A randomized controlled trial.","authors":"R Govind Reddy,&nbsp;Rajesh Vithal Gosavi,&nbsp;Babita Yadav,&nbsp;Amit Kumar Rai,&nbsp;Madhuri Prashant Holay,&nbsp;Manisha Talekar,&nbsp;Sophia Jameela,&nbsp;Bhagwan Sahay Sharma,&nbsp;Shruti Khanduri,&nbsp;Rakesh Rana,&nbsp;Arunabh Tripathi,&nbsp;Bhogavalli Chandrasekhararao,&nbsp;Narayanam Srikanth,&nbsp;Kartar S Dhiman","doi":"10.4103/ayu.ayu_14_21","DOIUrl":"https://doi.org/10.4103/ayu.ayu_14_21","url":null,"abstract":"<p><strong>Background: </strong>The evidence on the efficacy and safety of Ayurveda interventions as an add-on to the standard conventional care for coronavirus disease-2019 (COVID-19) is limited.</p><p><strong>Aim and objective: </strong>This study was planned to explore the potential of AYUSH-64 as an add-on to conventional care in improving the clinical recovery and negative reverse transcription-polymerase chain reaction (RT-PCR) conversion in asymptomatic and mild COVID-19 cases.</p><p><strong>Materials and methods: </strong>An open-label randomized controlled study was conducted at Government Medical College, Nagpur, Maharashtra, India, with a sample size of 60 participants. In this study, asymptomatic or mild COVID-19 patients were randomized and allocated into intervention and control groups (CG) in a 1:1 ratio. AYUSH-64 two capsules (500 mg each) were administered thrice daily, after food with water for 30 days along with standard care in the intervention group (IG), while the CG received only standard care. The primary outcome was the proportion of participants who turned RT-PCR negative for COVID-19 at 7^th, 15^th, 22^nd and 30^th days. Secondary outcomes were the proportion of participants who attained clinical recovery at 7^th, 15^th, 22^nd and 30^th days, change in laboratory parameters on the 30^th day and incidence of adverse drug reactions/adverse events. The data were compared within group using paired sample <i>t</i>-test/Wilcoxon signed-rank test and between group using independent sample <i>t</i>-test/Mann-Whitney test.</p><p><strong>Results: </strong>Statistically significant difference was not observed in the proportion of participants who turned RT-PCR negative during each of the follow-ups (<i>P</i> = 0.134) and both groups demonstrated comparable efficacy. The clinical recovery in terms of complete relief in symptoms in the symptomatic participants was 60% and 37% on day 15 (<i>P</i> = 0.098) and 100% and 85.2% on day 30 (<i>P</i> = 0.112) in the intervention and CG, respectively. The improvement in the inflammatory markers such as interleukin (IL)-6, tumor necrosis factor-α (TNF-α), and D-dimer was statistically significant (<i>P</i> < 0.05) in the IG, whereas in the CG, it was statistically significant for D-dimer only. None of the participants developed any complications nor were any significant ADR/AE observed in the groups.</p><p><strong>Conclusions: </strong>In patients with asymptomatic and mild COVID-19, AYUSH-64, as add-on to standard conventional care, contributed to improved clinical recovery and demonstrated potential in reducing the levels of pro-inflammatory markers such as IL-6 and TNF-α. Further, both the groups demonstrated comparable efficacy regarding negative RT-PCR for COVID-19.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":"41 2","pages":"107-116"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/46/93/AYU-41-107.PMC8614205.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39839024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ayurvedic management for a rare disorder Takayasu arteritis - A case report.","authors":"Sarvesh Kumar Singh,&nbsp;Kshipra Rajoria,&nbsp;Sanjeev Sharma","doi":"10.4103/ayu.AYU_61_19","DOIUrl":"https://doi.org/10.4103/ayu.AYU_61_19","url":null,"abstract":"<p><p>Takayasu arteritis (TA) is a rare disorder and it is a devastating condition of aorta. The presently available treatments for the condition in the modern medicine have limited benefits. This is case of TA which was better managed with Ayurvedic intervention. An Ayurvedic diagnosis for this case was <i>Siragata Vata</i> (vitiated <i>Vata Dosha</i> affecting the blood vessels). A 42-year-old woman was diagnosed with TA and treated on the line of management of <i>Siragata Vata</i> with <i>Shastikashali Pinda Swedana</i> (sudation with bolus of medicated cooked rice) for 16 days, <i>Erandamuladi Niruha Basti</i> (enema mainly with decoction) along with <i>Ashwagandha Taila Anuvasana</i> (enema with medicated oil) for 16 days in <i>Kala Basti Krama</i> (16 days in alternate order of decoction and oleation enema) followed by one day gap and then 7 days of <i>Nasya Karma</i> (nasal therapy) with <i>Triphaladi Taila</i> (oil) on alternate days along with a combination of Ayurvedic oral drugs [<i>Brihadvatachintamani Rasa</i>-125 mg, <i>Dashamula Kwatha</i>-40 ml, <i>Narsinha Churna</i> (powder)-3 g, <i>Yogaraja Guggulu</i>-1g (500mgx2tab) and <i>Shiva Gutika</i>-500 mg, twice a day for 1 month. Same <i>Panchakarma</i> procedures were repeated after 6 months. A similar combination of oral medications were continued in between and during this period. <i>Chyavanaprasha Aveleha</i> in the dose of 10g twice a day with milk were also added after completion of this treatment regime. Patient condition was assessed on Indian Takayasu Clinical Activity Score (ITAS-2010) for disease activity of TA. Satisfactory results were observed in the patient with improvement in ITAS-2010 scoring. TA may be managed with Ayurvedic drugs and <i>Panchakarma</i> procedures.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":"41 2","pages":"79-86"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/77/AYU-41-79.PMC8614210.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39839021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibacterial efficacy of different combinations of clove, eucalyptus, ginger, and selected antibiotics against clinical isolates of <i>Pseudomonas aeruginosa</i>.","authors":"Pankaj Kumar Sagar,&nbsp;Poonam Sharma,&nbsp;Rambir Singh","doi":"10.4103/ayu.AYU_101_19","DOIUrl":"https://doi.org/10.4103/ayu.AYU_101_19","url":null,"abstract":"<p><strong>Background: </strong>Nosocomial infections caused by multidrug-resistant <i>Pseudomonas aeruginosa</i> are commonly treated with conventional antibiotic which may lead to some serious side effects in the patients. Conventionally, medicinal plants, including clove, eucalyptus, and ginger, are used for the safe and effective treatment of several diseases.</p><p><strong>Aims and objectives: </strong>The aim and objective of this study is to evaluate the combined antibacterial efficacy of medicinal plants (clove, eucalyptus, and ginger) and selected antibiotic and also combined efficacy of different plants extracts against clinical isolates of <i>P. aeruginosa</i>.</p><p><strong>Materials and methods: </strong>A total of seven clinical isolates and one reference strain (PA01) of <i>P. aeruginosa</i> were included in this study. The antibacterial activity of crude methanol extracts of medicinal plants and selected antibiotics was screened using well-diffusion assay and their minimum inhibitory concentration (MIC) was determined by the microdilution method. Combined efficacy of ceftazidime and plant extracts was tested using standard checkerboard method and different plant extracts were evaluated using broth macrodilution method.</p><p><strong>Results: </strong>All of the seven clinical isolates of <i>P. aeruginosa</i> showed multidrug resistance pattern and were found highly sensitive to ciprofloxacin followed by ceftazidime and gentamicin. Clove exhibited better antibacterial activity as compared to eucalyptus and ginger. Synergistic interaction was found between ceftazidime and plants extracts against reference PA01 and clinical isolate 2. Highest two-fold reduction in MIC was found in the combination of clove-ginger against reference PA01 and clinical isolate 3.</p><p><strong>Conclusion: </strong>The selected medicinal plants are highly efficient for enhancing the antibacterial activity of antibiotic.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":"41 2","pages":"123-129"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/4e/AYU-41-123.PMC8614201.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39726023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}